Very seldom ( unless some CEO wants to fall on his sword) would anyone want to procure a bio that has make-it or break-it trial results on the horizon. Today, Ariad is cheap if the trials are positive and very expensive if the trials fail.
We'll have to wait awhile to find the real value of ariad.
Market Data 
Markets 
AI
